Becton Dickinson & Co Stock Price, News & Analysis

BD (Becton, Dickinson and Company) announced the launch of the BD COR™ System, a fully automated high-throughput diagnostic platform for infectious disease testing, specifically designed for core and centralized laboratories in the U.S. The system enhances laboratory efficiency by automating sample processing and diagnostics, eliminating extensive manual handling. Initially, it will support the BD Onclarity™ HPV Assay, capable of detecting multiple high-risk HPV types. This launch, following prior approval in Europe, marks a significant step in BD's molecular diagnostics strategy, enhancing capabilities for high-volume labs.

Becton, Dickinson and Company (NYSE: BDX) announced its tender offers for purchasing senior notes totaling $1,285,000,000. The offers include all of the Company’s 2.894% notes due 2022 and 3.300% notes due 2023, along with up to the maximum limits of several 2024 notes. Total Considerations for these notes are detailed, with early tender payments set at $30. The company expects to accept only those Maximum Tender Offer Notes validly tendered by the Early Tender Date of August 18, 2021. Investors are directed to the Offer to Purchase for complete terms.

Becton, Dickinson and Company (BD) announced early tender results for its cash tender offers on senior notes due 2022 and 2023, with a total maximum cap of $1.285 billion. As of August 18, 2021, $877.6 million of the 2.894% senior notes and $128.1 million of the 3.300% senior notes were tendered. The company plans to redeem any untendered 2.894% notes by September 13, 2021. The tender offers will lead to early settlements on August 20, 2021, with a prorated acceptance for certain notes exceeding their tender caps.

BD (Becton, Dickinson and Company) (NYSE: BDX) has announced the launch of the BD FACSymphony™ A1 Cell Analyzer, a benchtop system designed to enhance access to flow cytometry capabilities for laboratories of all sizes. This fluorescence-activated cell analyzer features advanced research capabilities and compact design, enabling efficient resource use and time-saving for researchers. The device supports various experiments from small particle studies to 16-color immunophenotyping, utilizing BD's industry-standard software for streamlined workflows.

BD (Becton, Dickinson and Company) has appointed Christopher DelOrefice as the new chief financial officer (CFO), effective Sept. 6, 2021, following Christopher Reidy's planned retirement. DelOrefice previously held key finance positions at Johnson & Johnson, contributing nearly two decades of experience in healthcare finance. His expertise will aid BD in executing its 2025 growth strategy and boosting shareholder value. DelOrefice's vast background, including roles in Investor Relations, positions him as a strong asset for BD's leadership team.

Becton, Dickinson and Company (NYSE: BDX) announced an amendment to its tender offers for certain Senior Notes due 2024. The maximum principal amount for its 3.734% Senior Notes has been increased from $300 million to $500 million, while the total maximum for all offered notes rises from $715 million to $1.285 billion. Other terms remain unchanged. The tender offers are outlined in the Offer to Purchase, dated August 5, 2021, which investors should carefully review for full details.

Becton, Dickinson and Company (NYSE: BDX) announced tender offers to purchase cash for its outstanding debt securities totaling up to $715 million. The offers include senior notes due in 2022 and 2023, along with specific notes due in 2024, with an emphasis on early tender payments for participants before the August 18 deadline. The tender offers will expire on September 1, 2021, or as extended. The company retains the right to increase tender cap limits and emphasizes the need for interested holders to review the Offer to Purchase for comprehensive details.

BD reported a strong third fiscal quarter, with revenues reaching $4.9 billion, a 26.9% increase year-over-year. COVID-19 testing revenues contributed $300 million, including $212 million from the BD Veritor™ Plus System. The GAAP diluted EPS surged 77.3% to $1.72, while adjusted diluted EPS grew 24.5% to $2.74. BD raised its fiscal 2021 revenue growth and adjusted EPS guidance, projecting revenue growth of 16.5% to 17.0% and adjusted EPS between $12.85 and $12.95.

BD (Becton, Dickinson and Company) announced the retirement of Christopher Reidy, its CFO and CAO, effective after a successor is appointed. Reidy, who joined BD in 2013, will transition to a director role at the upcoming independent Diabetes Care company after its expected spinoff in early 2022. During his tenure, he contributed significantly to BD's key acquisitions and financial functions. His leadership has been pivotal for the company’s momentum, as he expressed confidence in BD’s capacity to drive shareholder value and affect patient lives positively.